7LAW
crystal structure of GITR complex with GITR-L
7LAW の概要
| エントリーDOI | 10.2210/pdb7law/pdb |
| 分子名称 | Tumor necrosis factor ligand superfamily member 18, Tumor necrosis factor receptor superfamily member 18, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total) |
| 機能のキーワード | gitr-ligand, receptor, complex, signaling protein |
| 由来する生物種 | Homo sapiens (Human) 詳細 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 61649.56 |
| 構造登録者 | Longenecker, K.L.,Rogers, B.,Bigelow, L.,Judge, R.A.,Alvarez, H. (登録日: 2021-01-07, 公開日: 2022-03-09, 最終更新日: 2024-10-23) |
| 主引用文献 | Chan, S.,Belmar, N.,Ho, S.,Rogers, B.,Stickler, M.,Graham, M.,Lee, E.,Tran, N.,Zhang, D.,Gupta, P.,Sho, M.,MacDonough, T.,Woolley, A.,Kim, H.,Zhang, H.,Liu, W.,Zheng, P.,Dezso, Z.,Halliwill, K.,Ceccarelli, M.,Rhodes, S.,Thakur, A.,Forsyth, C.M.,Xiong, M.,Tan, S.S.,Iyer, R.,Lake, M.,Digiammarino, E.,Zhou, L.,Bigelow, L.,Longenecker, K.,Judge, R.A.,Liu, C.,Trumble, M.,Remis, J.P.,Fox, M.,Cairns, B.,Akamatsu, Y.,Hollenbaugh, D.,Harding, F.,Alvarez, H.M. An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy. Nat Cancer, 3:337-354, 2022 Cited by PubMed Abstract: Costimulatory receptors such as glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) play key roles in regulating the effector functions of T cells. In human clinical trials, however, GITR agonist antibodies have shown limited therapeutic effect, which may be due to suboptimal receptor clustering-mediated signaling. To overcome this potential limitation, a rational protein engineering approach is needed to optimize GITR agonist-based immunotherapies. Here we show a bispecific molecule consisting of an anti-PD-1 antibody fused with a multimeric GITR ligand (GITR-L) that induces PD-1-dependent and FcγR-independent GITR clustering, resulting in enhanced activation, proliferation and memory differentiation of primed antigen-specific GITRPD-1 T cells. The anti-PD-1-GITR-L bispecific is a PD-1-directed GITR-L construct that demonstrated dose-dependent, immunologically driven tumor growth inhibition in syngeneic, genetically engineered and xenograft humanized mouse tumor models, with a dose-dependent correlation between target saturation and Ki67 and TIGIT upregulation on memory T cells. Anti-PD-1-GITR-L thus represents a bispecific approach to directing GITR agonism for cancer immunotherapy. PubMed: 35256819DOI: 10.1038/s43018-022-00334-9 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.752 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






